Pliant Therapeutics, Inc. PLRX
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Pliant Therapeutics, Inc. (PLRX) is a healthcare company listed in the US with a market value of about $43M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -41%.
About Pliant Therapeutics
Pliant Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $57M in 2019 to $2M in 2023, a decline of about 59.2% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 46% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2M | $10M | $8M | $42M | $57M |
| Net income | -$149M | -$210M | -$161M | -$123M | -$97M | -$42M | -$631000 |
| Free cash flow | -$129M | -$159M | -$117M | -$96M | -$77M | -$39M | -$4M |
| EPS (diluted) | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 | $-1.95 | $-4.22 |
| Net margin | — | — | -10211.1% | -1273.3% | -1284.5% | -99.3% | -1.1% |
| ROIC | -58.7% | -49.5% | -30.0% | -30.5% | -37.4% | -11.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $2.00, 187% above the current price; targets range from $2.00 to $2.00; the consensus rating is “Hold”; expected EPS is $-1.44 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Pliant Therapeutics pay a dividend?
Not currently.
Is Pliant Therapeutics a good stock to buy?
We do not give buy or sell advice. Pliant Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.